News & analysis on the clinical development and manufacture of large molecule drugs
Nordic Nanovector, Lars Nieba
By Vassia Barba
- Last updated on
Lars Nieba leaves Bayer where he spent two years as VP and strategic product lead to join Nordic Nanovector, a clinical stage developer of cancer therapies, as its chief technology officer.
Prior to Bayer, Nieba spent 13 years at Roche, holding several leadership roles in clinical supply and biologics development.
Nieba’s role at Nordic Nanovector will be to oversee all chemistry, manufacturing and controls (CMC) strategic and operational for the company’s pipeline, including Betalutin (lilotomab), the lead product in development.
Nieba’s appointment will be effective on 1 December 2019.